Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting No phase listed Observational

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

ClinicalTrials.gov ID: NCT04515524

Public ClinicalTrials.gov record NCT04515524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary objectives of the study are: * To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of Retinopathy of Prematurity (ROP). * To evaluate long-term safety outcomes in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. Secondary objectives of the study are: * To describe visual function in patients included from the VGFTe-ROP-1920 study, for treatment of ROP. * To describe overall development in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.

Study identification

NCT ID
NCT04515524
Recruitment status
Active, not recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
100 participants

Conditions and interventions

Interventions

Other

Eligibility (public fields only)

Age range
11 Months to 5 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 4, 2021
Primary completion
Nov 4, 2026
Completion
Nov 4, 2026
Last update posted
Mar 26, 2026

2021 – 2026

United States locations

U.S. sites
9
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
UCSD Shiley Eye Institute, Jacobs Retina Center La Jolla California 92093-0946
Loma Linda University Eye Institute Loma Linda California 92354
University of California San Francisco - Ophthalmology San Francisco California 94158
New York University School of Medicine - Oncology New York New York 10016
Icahn School of Medicine at Mount Sinai New York New York 10029
University Hospitals Cleveland Medical Center Cleveland Ohio 44106
Lifespan - Women & Infants Hospital of RI Providence Rhode Island 02905
The Children's Hospital of San Antonio San Antonio Texas 78240
West Virginia University Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04515524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 26, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04515524 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →